High‐velocity nasal insufflation versus noninvasive positive pressure ventilation for moderate acute exacerbation of chronic obstructive pulmonary disease in the emergency department: A randomized clinical trial
In participants with symptomatic COPD, HVNI was noninferior to NiPPV in relieving dyspnea 4 h after therapy initiation. HVNI may be a reasonable treatment option for some patients experiencing moderate acute exacerbations of COPD in the ED.
Authors
- Andrew C. Meltzer (ORCID: https://orcid.org/0000-0001-5971-8314)
- Connor Kelly
- Ryan Heidish (ORCID: https://orcid.org/0000-0003-3749-9370)
- Jessica S. Whittle (ORCID: https://orcid.org/0000-0003-3177-8934)
- Christopher W. Jones (ORCID: https://orcid.org/0000-0001-9704-9094)
- R. Gentry Wilkerson (ORCID: https://orcid.org/0000-0001-8301-4421)
- George C. Dungan
- Joshua J Oliver (ORCID: https://orcid.org/0000-0001-6850-3497)
- David Yamane (ORCID: https://orcid.org/0000-0002-5101-2162)
- Taylor Bolden
- Amy Bergeski (ORCID: https://orcid.org/0000-0003-4618-9374)
- Aditya Loganathan (ORCID: https://orcid.org/0000-0001-7533-9285)
- Soroush Shahamatdar
- Richard Maisiak
Institutions
- University of Maryland, Baltimore (US)
- Madigan Army Medical Center (US)
- George Washington University (US)
- Phillips Exeter Academy (US)
- University of Alabama at Birmingham (US)
- Vapotherm (United States) (US)
- Cooper University Health Care (US)
Publication Details
- Journal
- Academic Emergency Medicine
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1111/acem.15038
- Citations
- 5
- Primary Topic
- Respiratory Support and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 2.09